Clinical Trials
15 trialsNCT05307705 2026-04-20
PIKASSO-01
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04572295 2026-03-11
A Study of E7090 as Monotherapy and in Combination With Other Anticancer Agents in Participants With Estrogen Receptor Positive (ER+) and Human Epidermal Growth Receptor 2 Negative (HER2-) Recurrent/Metastatic Breast Cancer
Eisai Inc.
Phase 1 Active not recruiting
NCT02057133 2026-01-26
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
Eli Lilly and Company
Phase 1 Active not recruiting
NCT07163481 2025-09-16
SoGreat
Hunan Cancer Hospital
Phase 1 Not yet recruiting
NCT03554044 2025-05-21
T-VEC With Chemotherapy or Endocrine Therapy in Treating Participants With HER2- Negative Breast Cancer
University of California, San Francisco
Phase 1 Completed
NCT02623751 2022-06-21
Study of KHK2375 in Subjects With Advanced or Recurrent Breast Cancer
Kyowa Kirin Co., Ltd.
Phase 1 Completed
NCT02820961 2021-12-15
Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer
Syndax Pharmaceuticals
Phase 1 Completed
NCT01594398 2021-11-19
ENCORE110
Syndax Pharmaceuticals
Phase 1 Completed
NCT01857193 2021-04-13
Phase Ib Trial of LEE011 With Everolimus (RAD001) and Exemestane in the Treatment of Hormone Receptor Positive HER2 Negative Advanced Breast Cancer
Novartis
Phase 1 Completed
NCT02077933 2020-12-08
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
Novartis
Phase 1 Completed
NCT01597193 2019-05-08
Safety Study of Enzalutamide (MDV3100) in Patients With Incurable Breast Cancer
Pfizer
Phase 1 Completed
NCT02833155 2019-05-07
Entinostat in Chinese Postmenopausal Women Patients With Locally Recurrent or Metastatic Breast Cancer
Taizhou EOC Pharma Co., Ltd.
Phase 1 Completed
NCT00933309 2016-02-19
The Impact of Obesity and Obesity Treatments on Breast Cancer
M.D. Anderson Cancer Center
Phase 1 Completed
NCT01149356 2015-05-25
RO4929097 And Exemestane in Treating Pre- and Postmenopausal Patients With Advanced or Metastatic Breast Cancer
National Cancer Institute (NCI)
Phase 1 Terminated
NCT01240928 2013-08-20
MK-2206+Endocrine Therapy in Patients With Hormone Receptor-Positive Breast Cancer
Vanderbilt-Ingram Cancer Center
Phase 1 Withdrawn